CABRI is proudly dedicated to research new treatments for rare diseases. To support this effort, we offer research grants to individual principal investigators at academic research institutions who have a plan to extend the clinical or pre-clinical development of our mission.
Eligible applicants include domestic and international researchers alike, along with domestic and international group collaborations. Our grants are open to investigators of any career stage who are capable of leading an independent research study and supervising personnel. Funds may only be used for research. CABRI does not fund institutional overhead costs.
PAST GRANT RECIPIENTS
2021 Grant Recipients
$74,855- Maria do Carmo Pereira da Costa, Research entitled: “NIK as a therapeutic target for Spinocerebellar ataxia type 3.”
Additional $100k to Sven Erik and his team, Research entitled: “Blocking the prostaglandin component of mast cell-dependent bronchoconstriction.”
$50k-Dr. Stefan Zwingenberger at the Center for Translational Bone, Research entitled: “Joint and Soft Tissue Research for Functionalization of biomaterials with KMN-159 to enhance bone quality in an osteoporotic drill hole model in rats.”
$75k-Dr. Floyd Chilton at the University of Arizona, Research entitled: “Impact of Circulating Secreted Phospholipase A2 Group IIA on COVID-19 and ARDS Pathogenesis, Organ Failure, and Death.”
$75,757 Dr. Laura Goodrich at Colorado State University, Research entitled: “Evaluation of the use of small novel compounds, KMN159 and KMN224, as osteogenic inducers in horse and sheep cultures” (2020, 2021).
$75k Dr. Marina Holz at New York Medical College, Research entitled: “Characterization of estrogen-mTORC1 signaling network in TSC/LAM (2020, 2021).
$70k Dr. Elias Arner of Karolinska Institute, Research entitled: “Inhibition of prostaglandin D2 biosynthesis: An unmet need in many inadequately treated diseases” (2020, 2021).
2020 Grant Recipients
$75,000- Dr. Sven-Erik Dahlen, Research entitled: “Inhibition of prostaglandin D2 biosynthesis: An unmet need in many inadequately treated diseases.” (2018, 2019, 2020.)
$60,000- Dr. Mike Holinstat, Research entitled: “ML355 regulation of platelet function, thrombosis, and bleeding in HIT” (2018, 2019, 2020.)
$50,000- Dr. Amanda Huber, Research entitled: “Mesenchymal Stem Cell specific Kdm6b regulates heterotopic ossification in Fibrodysplasia Ossifcans Progressiva.”
$15,000- David Aronoff, Research entitled: “Detection of Clostridium septicum alpha toxin by enzyme linked immunosorbent assay in an infection model” (2019, 2020.)
2019 Grant Recipients
$50,000 – Dr. Stefan Zwingenberger, University of Dresden Research entitled: “Enhancement of bone regeneration by functionalization of various bone substitution materials with a novel and potent lactam acetylene EP4 receptor agonist (KMN-159).”
2018 Grant Recipients
$50,000 – Dr. Sven-Erik Dahlen, Karolinska Institute Research entitled: “Inhibition of prostaglandin D2 biosynthesis: an unmet need in many inadequately treated diseases.”
$50,000 – Michael Holinstadt, University of Michigan Research entitled: “Assessing whether 12-LOX deficiency reduces incidences of thrombocytopenia.”Dr. Sven-Erik Dahlen
2017 Grant Recipients
$59,200 – Dr. Peter Krieg, DKFZ, Research entitled: ““Novel therapeutic approached for the treatment of autosomal recessive congenital ichthyoses (ARCI).”
$17,000 – Dr. Stefan Zwingenberger, University of Dresden Research entitled: “Enhancement of bone regeneration by functionalization of various bone substitution materials with a novel and potent lactam acetylene EP4 receptor agonist (KMN-159).”
2016 Grant Recipients
$50,000 – Migual Gijon, University of Colorado-Denver Research entitled: “Lipid mediators in urine as indicators of ongoing inflammation and progression of disease when mice are injected with maresin 1 into the peritoneal cavity.”
2015 Grant Recipients
$59,200 – Dr. Peter Krieg, DKFZ Research entitled: “Novel therapeutic approach for the treatment of autosomal recessive congenital ichthyoses (ARCI).”